The estimated Net Worth of Ralph L Mc Dade is at least $3.28 Million dollars as of 12 March 2019. Ralph Dade owns over 1,975 units of Myriad Genetics stock worth over $3,222,033 and over the last 10 years he sold MYGN stock worth over $61,225. In addition, he makes $0 as President - Myriad RBM at Myriad Genetics.
Ralph has made over 3 trades of the Myriad Genetics stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 1,975 units of MYGN stock worth $61,225 on 12 March 2019.
The largest trade he's ever made was selling 1,975 units of Myriad Genetics stock on 12 March 2019 worth over $61,225. On average, Ralph trades about 209 units every 50 days since 2014. As of 12 March 2019 he still owns at least 122,604 units of Myriad Genetics stock.
You can see the complete history of Ralph Dade stock trades at the bottom of the page.
Dr. Ralph L. McDade Ph.D. serves as President - Myriad RBM a subsidiary of the Company. Previously, he served as Chief Operating Officer of Myriad RBM. Dr. McDade was formerly Strategic Development Officer for Myriad RBM and was in that position since the company’s inception in 2002. Prior to joining Myriad RBM, he was Chief Scientific Officer for Luminex Corporation from 1996 to 2002, where he was closely involved with the development of xMAP technology. Dr. McDade received his Ph.D. in Microbiology from the University of Texas Southwestern Medical School in 1980. Following postdoctoral training at The University of Connecticut Medical Center in Farmington, he held faculty positions at the Rockefeller University in New York and at Louisiana State University School of Medicine in New Orleans.
Ralph McDade is 63, he's been the President - Myriad RBM of Myriad Genetics since 2014. There are 5 older and 20 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
Ralph's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: